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Abstract
Randomized controlled trials (RCTs) are conducted under idealized and rigorously controlled conditions that may
compromise their external validity. A literature review was conducted of published English language articles that
reported the findings of studies assessing external validity by a comparison of the patient sample included in RCTs
reporting on pharmaceutical interventions with patients from everyday clinical practice. The review focused on
publications in the fields of cardiology, mental health, and oncology. A range of databases were interrogated
(MEDLINE; EMBASE; Science Citation Index; Cochrane Methodology Register). Double-abstract review and data
extraction were performed as per protocol specifications. Out of 5,456 de-duplicated abstracts, 52 studies met the
inclusion criteria (cardiology, n = 20; mental health, n = 17; oncology, n = 15). Studies either performed an analysis of
the baseline characteristics (demographic, socioeconomic, and clinical parameters) of RCT-enrolled patients
compared with a real-world population, or assessed the proportion of real-world patients who would have been
eligible for RCT inclusion following the application of RCT inclusion/exclusion criteria. Many of the included studies
concluded that RCT samples are highly selected and have a lower risk profile than real-world populations, with the
frequent exclusion of elderly patients and patients with co-morbidities. Calculation of ineligibility rates in individual
studies showed that a high proportion of the general disease population was often excluded from trials. The
majority of studies (n = 37 [71.2 %]) explicitly concluded that RCT samples were not broadly representative of real-
world patients and that this may limit the external validity of the RCT. Authors made a number of recommendations to
improve external validity. Findings from this review indicate that there is a need to improve the external validity of
RCTs such that physicians treating patients in real-world settings have the appropriate evidence on which to base their
clinical decisions. This goal could be achieved by trial design modification to include a more representative patient
sample and by supplementing RCT evidence with data generated from observational studies. In general, a thoughtful
approach to clinical evidence generation is required in which the trade-offs between internal and external validity are
considered in a holistic and balanced manner.
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Background
Appropriately designed and executed randomized con-
trolled trials (RCTs) represent the current gold-standard
primary study design for the determination of the effi-
cacy and safety of medical interventions [1]. Evidence
from RCTs is used by healthcare providers to guide their
clinical decisions and by payers and policy makers to
support their recommendations for the adoption of new
therapies in clinical practice [2]. Explanatory RCTs are de-
signed to determine the efficacy of an intervention under
idealized and controlled circumstances and so are con-
ducted under rigorous conditions, including strict adher-
ence to structured protocols, the use of restrictive inclusion
and exclusion criteria, and patient randomization, that
maximize their internal validity (that is to ensure they
minimize the possibility of bias regarding the effect of an
intervention) [3, 4]. In order for the results of such trials to
be clinically useful, they must also be relevant to a definable
patient population in a specific healthcare setting, a concept
that is termed external validity or generalizability (note,
these terms are used interchangeably [3] in this review and
describe the applicability of the study results outside of the
trial environment) [5–7]. As it is challenging to simultan-
eously optimize internal and external validity, efficacy data
from traditional explanatory RCTs are often complemented
by evidence from pragmatic trials (including pragmatic
RCTs) or observational studies that determine the perform-
ance of an intervention under conditions more closely re-
sembling routine clinical practice, and include more
heterogeneous patient populations and less stringent treat-
ment and delivery protocols [4]. While some pragmatic tri-
als have good internal validity and some observational
studies may lack external validity, generally explanatory
RCTs tend to maximize internal validity at the expense of
external validity, while studies conducted in a setting more
closely resembling real-world practice may do the opposite.
As such, evidence from all these sources can be comple-
mentary in understanding the effect of an intervention and
furthering clinical research [8].
In recent years, the need to better understand the ex-
ternal validity of RCT results has been identified across
numerous therapeutic areas [9–13]. However, a compre-
hensive literature review of studies that have assessed
the representativeness of RCT populations has not been
undertaken in recent years (note, the term representa-
tiveness has been used throughout this review to de-
scribe the similarities between RCT samples and real-
world populations). To examine this issue, we conducted
a literature review of studies that have attempted to
evaluate external validity in one of two ways: (i) by com-
paring the clinical characteristics of an RCT sample with
those of everyday clinical practice patients, or (ii) by
assessing what proportion of a real-world population
would satisfy the criteria for RCT inclusion. In the
context of the current review, real-world populations are
defined as those patients encountered in routine clinical
practice settings (for example, patients included in ob-
servational cohorts or patients identified from medical
chart review, registries, or insurance databases). The pri-
mary objective of the review was to assess the extent to
which RCT samples are representative of real-world
populations (which may or may not affect the external
validity of the trial findings). Other objectives were to
identify key issues that may impact the external validity
of trial findings (with reference to included studies) and
also to outline recommendations from the identified
studies for improving external validity. The present re-
view was limited to RCTs in oncology, mental health,
and cardiology as, when the review was undertaken,
these were identified as the main therapeutic areas in
which RCT and real-world populations had been com-
pared. It should be noted that the focus of the current
review was explanatory and not pragmatic RCTs.
Review
Methods
The methodological framework of this literature review
was employed to examine the extent, range, and nature
of research activity regarding the representativeness of
RCT patient samples and the implications of this to the
external validity of the findings. The review involved a
five-stage process [14]: identification of the research
question; identification of studies relevant to the re-
search question; selection of studies to include in the re-
view; charting of information and data within the
included studies; collating, summarizing, and reporting
results of the review. A search protocol was written that
outlined the objectives, search methods, and the process
for study selection and data extraction.
Information sources, search approach, and strategy
Searches were run in MEDLINE and MEDLINE In-
Process, EMBASE, Science Citation Index, and the
Cochrane Methodology Register and were supplemented
with reference checking. When combined with citation
searching, these sources presented a reasonable basis for
a targeted search of the published literature. The
searches were run on 30 September 2013 and included
published studies conducted from 2003 to 2013 in order
to reflect contemporary clinical trial practice. A base-
case search strategy was created in the Ovid MEDLINE
interface, and once finalized, was adapted to meet the
syntax of the other databases. See Additional file 1 for
the full Ovid MEDLINE search.
Database searches were designed to identify primary
research studies published in English providing an ana-
lysis of an adult (aged > 18 years) patient sample in an
RCT (or number of RCTs or meta-analysis of RCTs)
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compared with an adult patient population treated outside
of an RCT setting with the same condition. Studies could
have quantitatively assessed how many patients in a real-
world population would satisfy the eligibility requirements
of an RCT, or compared the clinical characteristics of an
RCT sample with a real-world population. Only those stud-
ies reporting on pharmaceutical interventions studied as
part of an RCT (placebo-controlled or active comparator)
were included. Case reports, methodology papers, and con-
ference abstracts were not considered, nor were studies
that undertook an analysis of patients who were recruited
into an RCT compared with those that declined participa-
tion, or studies that involved a pediatric (aged < 18 years)
population. This analysis was limited to studies in cardi-
ology, mental health, and oncology, as the larger numbers
of publications identified in these therapeutic areas
allowed for a higher level synthesis of their findings.
Study selection, data extraction, and reporting
Search results were assessed for relevance by two inde-
pendent researchers by reviewing the title and abstract
of all identified studies. Studies meeting or potentially
meeting the review eligibility criteria were assessed in
more detail using the full text. A third reviewer (TKM)
resolved disagreements on study selection.
A data extraction table was developed and tested on a
sample of studies before further refinement. Data were
quality checked through double-data extraction by a sec-
ond researcher on 10 % of the records included to en-
sure the format of data extraction tables was
appropriate. All data included in the final manuscript
were quality checked. The following data were extracted
from each included publication: (i) generalizability objec-
tives; (ii) patient populations and country of study; (iii)
methods; (iv) description of RCT and real-world data
sources; (v) listing of comparisons made and key results;
(vi) overall conclusions; (vii) recommendations address-
ing identified issues and best practices.
Following a detailed review, a framework for the narra-
tive analysis of the data was developed that included
categorization of the identified studies by two methods.
Method A involved a formal statistical comparison (for
example, use of Wilcoxon rank sum test and chi-square
test for continuous and categorical variables, respect-
ively) of baseline characteristics between a real-world
patient population and a patient sample enrolled in an
RCT in the same specific disease area. Patients were
compared for baseline characteristics such as demo-
graphics, clinical and disease data, and treatments and
procedures. A range of different statistical methodolo-
gies were employed in the included studies, and it is out-
side of the scope of this review to detail them all; the
reader is referred to the individual studies for more in-
formation. Method B involved a determination of the
proportion of patients in a real-world population that
would have been trial eligible or ineligible by review of
individual patient medical records followed by the applica-
tion of explicit eligibility criteria derived from specific RCTs
or common criteria derived from a review of multiple RCTs
in the same disease to individual patient data. The ineligi-
bility rates as calculated in each individual Method B study
were tabulated and the distribution by quartiles examined.
A minority of studies employed a mixture of methods (A
and B) and presentation of the findings from such studies
was split by method (Tables 2 and 3).
In order to interpret the main findings of the literature
review as they related to external validity, a qualitative
synthesis of individual study results was undertaken.
The discussion and conclusions of each publication were
closely studied by one researcher, and the subjective au-
thor conclusions with respect to “external validity”,
“generalizability”, or “representativeness” were tabulated.
These were then grouped according to the precise word-
ing used by individual authors and categorized as: “Dif-
ferent” if the authors explicitly commented that, in their
opinion, there were meaningful differences between
RCT samples and real-world populations that suggested
they were not representative, that the data could not be
extrapolated or were not applicable to real-world settings,
and/or that external validity is impacted; “Not Explicit” if
the authors did not explicitly comment on external valid-
ity or did not comment on external validity despite dem-
onstration of differences in baseline characteristics;
“Similar” if the authors commented that populations were
similar and/or RCT results were generalizable to the over-
all disease population. A second researcher checked the
grouping of each study by category; in the event of any
disagreements, the findings of each paper were discussed
until resolution was reached.
Results
Search results
The study selection is shown in Fig. 1. The original
search returned 5,456 studies of which 46 in the areas of
cardiology, mental health, and oncology were identified
as relevant after abstract review. An additional six stud-
ies were identified through citation searching.
Study design
Of the 52 studies included, 18 (34.6 %) employed only
Method A (comparison of baseline characteristics) while 27
(51.9 %) employed only Method B (determination of per-
centage ineligibility) (Table 1). An additional seven studies
(13.5 %) used both Methods A and B. The highest number
of studies was conducted in the USA (Table 1). The popula-
tions studied using Method A were compared for demo-
graphics, clinical characteristics, baseline treatments and
procedures, and other variables (Table 1). Additional
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analyses were conducted in some Method B studies as de-
tailed in Table 1. The sources and settings from which RCT
samples and real-world patient populations were drawn are
listed in Tables 2 and 3 (a more detailed summary of
sources is provided in Additional file 2).
Representativeness/external validity
In 37 (71.2 %) studies (12 [66.7 %] Method A; 19
[70.3 %] Method B; 6 [85.7 %] Method A/B), the individ-
ual study authors concluded that RCT samples were not
representative of patients encountered in clinical prac-
tice and/or that population differences may have a rele-
vant impact on the external validity of the RCT findings
[15–51]. The remaining 15 studies [52–66] did not reach
an explicit conclusion regarding external validity or con-
cluded that populations were broadly similar, although we
note that in some cases the authors still reported differ-
ences between RCT samples and real-world populations
(Tables 2 and 3) [53, 57, 62, 64, 65].
Cardiology
Studies included in the review generally demonstrated
that, compared with patients enrolled in major cardi-
ology RCTs, patients encountered in everyday practice
were more likely to have higher risk characteristics as
they were older, more likely to be female and to have
clinical impairment and co-morbid disease, were treated
less frequently with guideline-recommended therapy,
and received fewer in-hospital procedures (Table 2).
When RCT inclusion/exclusion criteria were applied to
real-world cardiology patients (Method B), those patients
who would have been ineligible for RCT participation were
more likely to be older and female, to have co-morbid dis-
ease, and to less frequently receive guideline-recommended
therapy compared with patients who would have been eli-
gible for the trial (Table 3). In 11 studies employing Method
B, 18 different sets of eligibility criteria were applied to real-
world populations and ineligibility rates reported; in eight
cases (44.4 %) more than 50 % of patients were reported to
Fig. 1 Study selection for a literature review assessing the external validity of randomized controlled trials
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be ineligible for trial inclusion (Fig. 2 and Table 3). The rea-
sons for ineligibility varied considerably by study depending
on the specific condition under assessment.
Mental health
In general, the identified studies reported that real-world
patients with mental health disorders tended to be more se-
verely ill than patients enrolled in RCTs. They also ap-
peared to have more co-morbidities and, in some cases,
lower overall functioning and socioeconomic status
(Table 2). Studies that assessed the characteristics of a real-
world population after the application of specific RCT in-
clusion/exclusion (Method B) reported that patients who
would have been RCT ineligible were older, had more co-
morbidities and more severe disease, exhibited lower over-
all functioning, and had lower socioeconomic status than
patients who would have been eligible for trial participation
(Table 3). In the 15 studies employing Method B, 18 differ-
ent sets of eligibility criteria were applied to real-world pop-
ulations resulting in ineligibility rates in excess of 50 % in
16 (88.9 %) cases (Fig. 2 and Table 3). Common reasons for
RCT exclusion across studies included current or history of
substance abuse, suicide risk, presence of co-morbidities
(such as other Axis I disorder, co-morbid anxiety, and other
central nervous system [CNS] or neuromuscular disorder),
insufficient symptom duration or low disease severity (in
studies of major depressive disease), contraindicated medi-
cation, and significant medical condition (see Additional
files 3 and 4).
Oncology
Compared with RCT-enrolled patients, real-world pa-
tients with cancer were often older, and more likely to
be female, have a poor performance status, and worse
disease prognosis (Table 2) in the studies selected in this
review. A single study compared the baseline character-
istics between RCT ineligible versus eligible patients
after the application of inclusion/exclusion criteria and
found that ineligible patients with colorectal cancer had
a worse performance status (Table 3) [58]. In the eight
studies employing Method B, 18 different sets of eligibil-
ity criteria were applied to real-world populations, with
ineligibility rates greater than 50 % being reported in 12
(66.7 %) cases (Fig. 2 and Table 3). Reasons for trial ex-
clusion included poor performance status, previous his-
tory of cancer, co-morbidities, reduced life expectancy,
CNS or brain metastases, and older age (see Additional
files 3 and 4).
Potential factors influencing the external validity of RCTs
In the majority of included studies, the authors made
some attempt to identify factors influencing the external
validity of RCTs. These could broadly be divided into ex-
plicit and implicit factors: explicit factors are the inclu-
sion/exclusion criteria listed in the study protocol, while
implicit factors include other issues that may affect patient
participation in any given trial. The influence of implicit
factors on external validity could only be hypothesized in
the included studies and are outlined below.
Explicit factors (restrictive inclusion/exclusion criteria)
Explicit factors were identified as a key driver for differ-
ences in RCT samples and real-world populations, as
demonstrated by the often high rates of trial ineligibility
(Fig. 2 and Table 3) determined in the included studies.
By using restrictive inclusion/exclusion criteria, higher risk
patients are effectively excluded from RCTs. For example,
in cardiology studies, patients often appeared to be ex-
cluded on the basis of older age and presence of co-
morbid disease. The authors of these studies suggested





Total number of studies 20 (38.5) 17 (32.7) 15 (28.8) 52 (100)
Geography
USA 8a (40.0) 10 (58.8) 5 (33.3) 23 (44.2)
The Netherlands 1 (5.0) 3 (17.6) 2 (13.3) 6 (11.5)
Germany 1 (5.0) 2 (11.8) 2 (13.3) 5 (9.6)
Canada 3 (15.0) 1 (5.9) 1 (6.7) 5 (9.6)
Other 7 (35.0) 1 (5.9) 5 (33.3) 13 (25.0)
Methodb
A only 9 (45.0) 2 (11.8) 7 (46.7) 18 (34.6)
B only 9 (45.0) 12 (70.6) 6 (40.0) 27 (51.9)
A and B 2 (10.0) 3 (17.6) 2 (13.3) 7 (13.5)
Comparisons made, Method Ac,d
Demographics 10 (90.9) 5 (100) 8 (88.9) 23 (92.0)
Clinical characteristics 8 (72.7) 5 (100) 7 (77.8) 20 (80.0)
Treatments and
procedures
4 (36.4) 2 (40.0) 3 (33.3) 9 (36.0)
Othere 1 (9.1) 1 (20.0) 0 (0.0) 2 (8.0)




6 (54.5) 6 (40.0) 1 (12.5) 13 (38.2)
Common reasons for
trial ineligibility
7 (63.6) 14 (93.3) 8 (100) 29 (85.3)
aIncludes one study conducted in the USA and Canada. bMethod A, formal
statistical comparison of baseline characteristics between a real-world patient
population and patients enrolled in a randomized controlled trial (RCT) in the
same disease area; Method B, determination of the proportion of real-world
patients who would have been trial eligible or ineligible by review of individual
patient medical records followed by application of RCT eligibility criteria. cEach
study made multiple comparisons. dPercentages calculated based on total
number of studies employing method (for example, Method A studies plus
Method A/B studies). eOther comparisons included physical activity relative to
“others the same age” (n = 1 cardiology study) and personality traits (n = 1
mental health study)
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that cardiovascular disease may represent a more compli-
cated syndrome in such patients [15] and that they are
more likely to experience adverse events [16, 19]. As such,
the results from these studies may not provide a
complete picture of anticipated drug efficacy and safety
in clinical practice. Female patients were also under-
Table 2 Key results and main author conclusions from Method A studies
Study Real-world data source Key differences (real-world versus RCT patients) Main author
conclusionsb
Cardiology
Badano et al., 2003 [15] MC-PR Older, more female, higher rates of concomitant diabetes,
greater LVF clinical impairment
Different
Björklund et al., 2004 [17] MC-PR Older, more female and more CV risk factors Different
Costantino et al., 2009a [21] SC-PR Older, more female, lower NYHA class Different
Dhruva et al., 2008 [22] ID Older, more female Different
Ezekowitz et al., 2012 [24] MC-PR Older, more female, more co-morbidities/prior cancer Different
Golomb et al., 2012 [27] MC-PR Increased self-rated physical activity with increasing age Different
Hutchinson-Jaffe et al., 2010 [29] MC-PR Older, more female, more co-morbidities, less guideline-
recommended treatment/procedures
Different
Melloni et al., 2010 [37] MC-PR More female Different
Steinberg et al., 2007 [62] MC-PR Older, more co-morbidities/CVD history NE
Uijen et al., 2007a [44] MC-PR Older, more female, higher CVD risk Different
Wagner et al., 2011 [65] ID Older, more chronic diseases NE
Mental health
Kushner et al., 2009 [57] MC-PR Greater depression severity (some scales), lower preference
for novel experiences
NE
Rabinowitz et al., 2003a [59] MC-PR No major differences Similar
Riedel et al., 2005 [60] SC-PR Older, longer duration of illness, more internistic co-morbidities/
hospitalizations
Similar
Surman et al., 2010a [42] SC-PR More co-morbidities, anxiety/depression, alcohol/substance
dependence
Different
Zarin et al., 2005a [49] MC-PR Older, more female/Caucasian Different
Oncology
Baquet et al., 2009 [52] MC-PR Fewer females (non-sex-specific tumor RCTs), fewer males
(sex-specific tumor RCTs)
NE
Elting et al., 2006 [23] SC-PR Older, more females/chronic co-morbidities, worse health/performance
status
Different
Fraser et al., 2011a [25] MC-PR Worse disease prognosis, more drug-related toxicity, lower
drug dose intensity
Different
Jennens et al., 2006 [30] MC-PR Older Different
Kalata et al., 2009 [31] MC-PR Older, more females, worse prognosis Different
Mengis et al., 2003a [38] SC-PR Older, worse performance status, more infections/AML-MDS
subtypes
Different
van der Linden et al., 2014 [45] MC-PR Older, more females, poor prognostic factors Different
Yennurajalingam et al., 2013 [48] SC-PR Older, more males, higher symptom intensity scores Different
Yessaian et al., 2005 [66] MC-PR No major differences Similar
Please see Additional files 2 and 3 for more detailed results
aStudies that employed Methods A and B; in these studies RCT and real-world populations were compared, the authors then used the eligibility criteria from the
RCT of interest to determine how many patients would hypothetically have been eligible or ineligible for that trial. Results presented in this table are for Method
A only (see Table 3 for Method B results). bDifferent: authors explicitly comment, in their opinion, that there were meaningful differences between populations that
suggested they were not representative, that the data could not be extrapolated or were not applicable to real-world settings, and/or that external validity is
impacted; NE: authors do not explicitly comment on external validity or do not comment on external validity despite demonstration of differences in baseline
characteristics; Similar: authors comment that populations are similar and/or that RCT results are generalizable to the overall disease population
AML acute myeloid leukemia, CV cardiovascular, CVD cardiovascular disease, ID insurance data; LVF left ventricular function, MC-PR patient records - multicenter
(including multicenter registries), MDS myelodysplastic syndrome, NYHA New York Heart Association, RCT randomized controlled trial, SC-PR patient records -
single center
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Table 3 Key results and main author conclusions from Method B studies
Study Real-world data
source
% ineligibilitya Key differences (ineligible versus eligible patients) Main author
conclusionsb
Cardiology
Bahit et al., 2003 [16] MC-PR 33.6 Older, more females/previous MI, lower ASA use,
longer LOS
Different
Bosch et al., 2008 [19] SC-PR 41.2 Older, higher risk profile Different
Collet et al., 2003 [53] SC-PR 34.0 Older, more females, higher risk score, fewer
in-hospital procedures
NE
Costantino et al., 2009c [21] SC-PR 66.2 ND Different
Fortin et al., 2006 [55] MC-PR 1.4–65.5 ND NE
Koeth et al., 2009 [34] MC-PR 46.4 Older, more females, more diabetes/hypertension,
less guideline-recommended treatment
Different
Krumholz et al., 2003 [56] MC-PR 84.5 (NRMI) ND Similar
90.6 (CCP)
Lenzen et al., 2005 [35] MC-PR 61.6 Older, more females, more co-morbid hypertension/
ACS/renal impairment, less guideline-recommended
treatment at baseline
Different
Masoudi et al., 2003 [36] ID 67.0 ND Different




Uijen et al., 2007c [44] MC-PR 53.0 ND Different
Mental health
Blanco et al., 2008 [18] GP 75.8 ND Different
Goedhard et al., 2010 [26] SC-PR 69.8 Older, more Axis II personality disorders Different
Hoertel et al., 2013 [28] GP 58.2 (bipolar) ND Different
55.8 (mania)
Keitner et al., 2003 [32] SC-PR 85.5 ND Different
Khan et al., 2005 [33] GP 98.2 ND Different
Rabinowitz et al., 2003c [59] MC-PR 33.0 ND Similar
Seemuller et al., 2010 [61] MC-PR 69.0 Younger, trend to younger age at disease onset Similar
Storosum et al., 2004 [41] SC-PR 83.8d ND Different
Surman et al., 2010c [42] SC-PR 61.0 More lifetime co-morbidity, lower overall functioning/
SES
Different
Talamo et al., 2008 [63] SC-PR 77.6 Few differences Similar
van der Lem et al., 2011 [64] SC-PR 75.5–81.2e ND NE
Wisniewski et al., 2009 [47] MC-PR 77.8 Older, less educated, more black/Hispanic, longer
disease duration, history of suicide and substance
abuse, more atypical features
Different
Zarin et al., 2005c [49] MC-PR 55.0 (bipolar) 38.0
(schizo-phrenia)
More co-morbidity, lower global functioning, greater
use of antipsychotic medication
Different
Zetin and Hoepner, 2007 [50] SC-PR 91.4 ND Different
Zimmerman et al., 2004 [51] SC-PR 65.8 ND Different
Oncology
Clarey et al., 2012 [20] SC-PR 31.0–76.0 ND Different
Filion et al., 2012 [54] SC-PR –f ND Similar
Fraser et al., 2011c [25] MC-PR 14.9 ND Different
Mengis et al., 2003c [38] SC-PR 87.0 ND Different
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represented in the cardiology trials identified in this review
[15, 17, 24, 29, 37]; one of the reasons for this may be due
to cardiovascular disease affecting women later in life,
meaning that upper age limit restrictions may dispropor-
tionately limit their inclusion in RCTs relative to men [37].
In mental health studies, high proportions of patients were
excluded on the basis of substance abuse, which is a par-
ticular issue for the external validity of trials in bipolar pa-
tients where rates are high [41]. One study applied only the
exclusion criteria that the authors considered strictly neces-
sary with respect to safety and found that nearly 75 % of pa-
tients with depression were still ineligible for participation
in efficacy RCTs [50]. Patient samples in oncology trials
were often found to have better disease prognosis and bet-
ter performance status compared with real-world patients
with cancer [23, 25, 31, 38, 45]. Inadequate performance
status (for example, Eastern Cooperative Oncology Group
performance status ≥ 2) was one of the most common rea-
sons for trial exclusion in several studies [20, 39, 46, 58].
Implicit factors
Implicit factors that may have affected the external validity
of RCTs were also identified in some of the studies
reviewed. Two cardiology studies noted that issues with
informed consent, whereby the most severely ill patients
are less likely to give informed consent or it is harder to
gain informed consent, may lead to the selection of lower
risk patients for trial participation [16, 17]. In addition,
one study indicated that psychiatric patients with more se-
vere aggression were also less likely to consent to enter an
RCT [26]. The type of RCT setting and/or recruitment
method were also discussed as potential barriers to trial
participation [26, 33, 49]; for example, one study that eval-
uated how many patients with schizophrenia would be eli-
gible for antipsychotic clinical trials suggested that there
could be discrepancies between subjects who were re-
cruited through advertisement and those recruited in a
clinical setting [33]. In oncology patients (and their physi-
cians), one of the biggest barriers to trial participation was
noted to be fear of randomization to the placebo arm [43].
A number of other patient-related factors were also
identified, including logistical issues related to study
participation, beliefs and attitudes regarding the safety
Table 3 Key results and main author conclusions from Method B studies (Continued)
Mol et al., 2013 [58] MC-PR 21.5 Worse performance status, higher alkaline phosphatase,
less primary tumor resection
Similar
Somer et al., 2008 [39] SC-PR 71.0 ND Different
Terschüren et al., 2010 [43] MC-PR 35.9 (HL) ND Different
70.4 (hgNHL)
Vardy et al., 2009 [46] MC-PR 65.0–72.0 ND Different
Please see Additional files 2 and 4 for more detailed results
aPercentage of patients not eligible for RCT inclusion following the application of eligibility criteria. bDifferent: authors explicitly comment, in their opinion, that
there were meaningful differences between populations that suggested they were not representative, that the data could not be extrapolated or were not
applicable to real-world settings, and/or that external validity is impacted; NE: authors do not explicitly comment on external validity or do not comment on
external validity despite demonstration of differences in baseline characteristics; Similar: authors comment that populations are similar and/or that RCT results
are generalizable to the overall disease population. cStudies that employed Methods A and B; in these studies RCT samples and real-world populations were compared,
the authors then used the eligibility criteria from the RCT of interest to determine how many patients would hypothetically have been eligible or ineligible for that trial.
Results presented in this table are for Method B only (see Table 2 for Method A results). dPercentage of manic episodes not number of ineligible. e75.5 % based on
application of stringent criteria using the Mittman regression equation to calculate HAM-D; 81.2 % based on application of stringent criteria using the Hawley or
Zimmerman regression equation to calculate HAM-D. fInclusion/exclusion criteria were categorized to identify criteria that might impede RCT recruitment; if any
individual category was not met by > 10 % of patients with breast cancer from a retrospective cohort, then the criterion was considered a barrier to recruitment. ACS
acute coronary syndrome, ASA aspirin, CABG coronary artery bypass graft, CCP cooperative cardiovascular project, GP general population data, HL Hodgkin’s lymphoma,
hgNHL high-grade non-Hodgkin’s lymphoma, ID insurance data, LOS length of stay, MC-PR patient records - multicenter (including multicenter registries and
observational studies), MI myocardial infarction, ND not determined, NRMI National Registry of Myocardial Infarction, PAD peripheral arterial disease, SC-PR patient
records - single center, SES socioeconomic status, TIA transient ischemic attack
Fig. 2 Proportion of real-world patients ineligible in randomized
controlled trials (RCTs) after application of inclusion/exclusion criteria.
Method B studies. Some individual studies reported multiple ineligibility
rates derived from the application of selection criteria from a number of
different RCTs to a single real-world population. Hence, in the 34 studies
that employed Method B, 54 different ineligibility rates were calculated
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of trial medications, cultural factors, level of satisfac-
tion with current treatment, and willingness to partici-
pate [39, 43, 48, 49]. Finally, one study demonstrated
that patients who participate in trials may have differ-
ent personality traits than those who do not; patients
with depression who were enrolled in an antidepressant
medication RCT were found to score more highly on a
personality scale that assessed preferences for novel ex-
periences compared with non-participants [57].
Study recommendations for the improvement of external
validity
Many of the studies included in the present review made
recommendations to improve the external validity of
RCTs. These recommendations are outlined in Table 4
and include modifying RCT design to improve external
validity directly, and generating complementary evidence
from alternative study types to address the limited exter-
nal validity of the RCT post hoc.
Discussion
The present analysis utilized a robust literature review
methodology to identify studies that compared the clinical
characteristics of an RCT sample and patients from a real-
world source (Method A) or assessed the proportion of a
real-world population that would satisfy criteria for RCT
inclusion (Method B). Publications identified by this meth-
odology indicated that RCT samples in cardiology, mental
health, and oncology studies that assessed pharmaceutical
interventions in adult patients were often not broadly rep-
resentative of patients treated in everyday clinical practice
and that caution should be exercised when extrapolating
data from trials to patients treated in usual care settings.
Note that, with the exception of a single study [40], none
of the RCTs described in the included studies were docu-
mented as being of a pragmatic design. In this Method B
study, the RCTs in acute coronary syndrome from which
eligibility criteria were extracted were described as having
pragmatic enrollment strategies; however, the analysis still
suggested that there were important differences in risk
profile between RCT eligible and ineligible patients [40].
Differences in demographics, clinical characteristics, and
treatments and procedures were reported between RCT
and real-world patients by studies that employed Method
A in their analyses [15, 17, 21–25, 27, 29–31, 37, 38, 42,
44, 45, 48, 49]. Similarly, when specific RCT inclusion/
exclusion criteria were applied to real-world populations
(Method B), important differences with respect to demo-
graphics and clinical and treatment parameters were iden-
tified between patients who would have been RCT
ineligible compared with those who would have been eli-
gible for the trial [16, 18–21, 25, 26, 28, 32–36, 38–44, 46,
47, 49–51]. Furthermore, it was observed that large pro-
portions of the general disease population were often ex-
cluded from trial participation. We note that some
differences in generalizability were observed between the
different therapeutic areas studied in the present review.
In only a minority of studies did the authors conclude
that RCT samples were broadly representative of real-
world populations and that external validity was not im-
pacted, or failed to reach an explicit conclusion regarding
external validity despite demonstrating some differences
in baseline characteristics between groups [52–66]. These
findings are largely consistent with a previously published
systematic sampling review that assessed the nature and
extent of exclusion criteria among RCTs published be-
tween 1994 and 2006 in selected medical journals with
impact factors > 2.5 [2]. While involving the review of
older studies and use of more restrictive search criteria
Table 4 Recommendations for managing external validity
issues made by included studies
Patient populations
Broadening of RCT inclusion and exclusion criteria [19, 20, 29, 31–33, 36,
38, 40, 42, 44, 47, 49]
Selection of patients from more appropriate settings/populations to
achieve a more representative sample (for example, prospective use of
registry data; a priori estimation of patient eligibility by application of
trial exclusion criteria to the target population) [15, 17, 18, 31, 44, 54]
Conduct of RCTs in specific patient subgroups [20, 28, 30, 31, 46]
Standardization of inclusion/exclusion criteria and diagnostic and
screening assessments across RCTs in a given medical condition [51]
Intervention
Broader range of RCT treatments (that is, different and realistic dosing
regimens, use of concurrent therapy, and appropriate duration of
treatment); comparison of new treatments with treatments as usual
rather than to a prescribed dose of a particular medicine [49]
Reporting
Improved reporting of populations and results (that is, greater
transparency in the reporting of how exclusion criteria are
operationalized and how this influences eligibility, and of the rate and
major characteristics of excluded patients) [28, 38, 51]
Collection, reporting, and comparison of data from patients within and
outside of the trial [24, 28, 63]
Analysis
Development of statistical analysis plans and power calculation
adjustment to ensure adequate powering for subgroup analyses [20, 37]
Generation of supportive data
Conduct of observational studies after the demonstration of treatment
efficacy at the RCT level [15, 23, 36]
Development of large patient registries in specific disease areas [19]
Adoption of pragmatic studies [48, 49]
Clinical practice recommendations
Prospective auditing of drug efficacy and safety in everyday practice
settings and comparison of these data with RCT results [25]
Provision of more detailed product information to include the criteria by
which patients were selected in pivotal RCTs [20]
RCT randomized controlled trial
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than the present review, this earlier study also demon-
strated that RCTs often exclude large proportions of the
general disease population and specific patient groups
from trial participation. In agreement with the present re-
view, it was reported that the elderly, women, and patients
with co-morbidities were frequently ineligible for trial in-
clusion [2]. However, note that RCT findings may still be
externally valid even in circumstances where the patient
sample is not broadly representative of the real-world
population. For example, one study included in the
present review concluded that patients with unstable an-
gina or non-ST-segment elevation myocardial infarction
who would have been excluded from enoxaparin RCTs
could be safety treated in clinical practice [53].
That the external validity of RCT results is often limited
is widely acknowledged by clinicians as a problem when it
comes to extrapolating data to the patients seen in every-
day practice [3, 7]. Indeed, it is an often-cited reason for
the frequent underuse of guideline-recommended therap-
ies [67]. Where there is no evidence of efficacy in specific
patient groups, clinicians may well be right in withholding
treatment so as to prevent unanticipated harm [35]. This
situation could, however, mean that patients at highest
baseline risk who might be expected to receive the most
benefit from a particular therapy are undertreated. This
so-called “treatment-risk paradox” has been well de-
scribed, particularly in cardiology [6].
In the studies included in the present review, the use of
restrictive inclusion/exclusion criteria in RCTs was identi-
fied as being one of the key factors that limited the exter-
nal validity of trial findings. Authors reported that
frequently excluded patients were the elderly, females, or
those with co-morbidities in cardiology studies [15–17,
19, 24, 29, 34, 35, 40, 44, 53, 55], patients with evidence of
substance abuse or co-morbid psychological disorders in
mental health studies [18, 28, 32, 33, 41, 42, 47, 49, 50, 61,
64], and patients with poor disease prognosis in oncology
studies [20, 25, 31, 38, 39, 45, 46]. These RCT populations
were, therefore, often highly selected and represented a
patient sample at much lower risk of adverse events and
complications compared with patients in clinical practice.
The use of stringent selection criteria in RCTs ensures a
homogeneous patient sample, optimizes internal validity
of the study by reducing variance and removing potential
confounding, so increasing the likelihood of finding a true
association between treatment exposure and outcomes
(that is, it makes it easier to distinguish the “signal”
[treatment effect] from the “noise” [bias and chance])
[68, 69]. While the use of highly selected populations
does not necessarily imply that a given treatment
under study would fail to have equivalent efficacy and
safety in under-represented patient groups, it does
create uncertainty that can only be dispelled through
the generation of additional evidence. However, it is
pertinent to also consider how inclusion of high-risk pa-
tients may affect the outcomes of traditional trials. Patients
with more co-morbidities or co-interventions may be more
likely to prematurely discontinue study participation, which
could lead to high attrition rates and a negative impact on
trial validity and outcomes.
The studies reviewed herein made several recommen-
dations to either improve the external validity of RCTs
or compensate for limitations thereof. These included
adaptation of trial designs to include a more heteroge-
neous patient sample that better represents different
subgroups such as the elderly or patients with co-
morbidities [19, 20, 28–33, 46]. Some studies suggested
that adoption of pragmatic trial designs may be a way
forward [48, 49]. Traditional RCTs are often described
as “explanatory” trials since they aim to evaluate treat-
ment efficacy under idealized conditions, and to explore
“if and how an intervention works”. In contrast, prag-
matic trials evaluate the effects of an intervention under
usual conditions and their designs seek to determine “if
an intervention actually works in real-life” [70]. In recent
years, the Pragmatic–Explanatory Continuum Indicator
Summary (PRECIS) tool has been developed, and has
now been updated with the PRECIS-2 version to allow
trialists to design studies that better support the needs
of the intended users of the results. PRECIS-2 consists
of nine domains (including “participant eligibility cri-
teria”) in which design decisions are made to determine
the extent to which the trial is pragmatic or explanatory,
and to help ensure that the design achieves the primary
purpose of the trial [71]. In addition to its application as
an aid to trial design, PRECIS-2 has the potential for use
in the assessment of completed trials for methodological
quality and the likelihood of outcome bias in much the
same way as the current Grading of Research, Assess-
ment, Development and Evaluation (GRADE) system is
used to assist guideline developers.
There is growing interest in different analytical
methods that utilize data from multiple studies to extend
and complement the evidence provided by a single clin-
ical trial. Meta-analysis [72, 73] can be used to combine
evidence from multiple clinical trials to provide a more
valid estimate of treatment effect, assuming the studies be-
ing combined are similar enough to permit synthesis.
Cross-design synthesis is a type of meta-analysis in which
evidence from studies with complementary designs are
combined in an effort to leverage complementary strengths
(such as internal validity of RCTs and external validity of
observational studies) and minimize the weaknesses of each
[74]. Another approach that leverages real-world data to ex-
tend findings from a traditional trial involves development
of propensity scores that predict, for each trial sub-
ject, membership in a corresponding real-world popu-
lation [75, 76]. Subjects over-represented in the clinical
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trial relative to the target real-world population receive
lower weights while those under-represented receive
higher weights. The resulting weights can be used to
understand differences between the trial and target real-
world populations, and to “project” the RCT efficacy to
the target population, in effect providing an estimate of
the efficacy that would be observed were the trial to be
conducted in a more representative everyday practice
population [75, 76]. Finally, simple descriptive analysis of
real-world data can also be employed in the trial planning
stages to better understand the impact of specific design
decisions (for example, potential exclusion criteria) on the
anticipated generalizability of the trial results and so im-
prove design. Adaptation of statistical analysis plans was
recommended by two of the studies reviewed here as a
method to facilitate analysis of important patient sub-
groups [20, 37].
Several of the reviewed studies highlighted incomplete
reporting as a potential issue for the external validity of
RCTs [24, 28, 38, 51, 63]. Improvements in trial report-
ing to provide a more detailed description of RCT sam-
ples would enable clinicians to better assess the external
validity of RCTs and so more accurately extrapolate trial
findings to their own patients. Following reporting
guidelines such as CONSORT, which is a requirement
for publication in many peer-reviewed journals [1], may
go some way to address issues of inconsistent reporting
and may provide greater transparency with respect to
trial eligibility.
Trials should follow the need for evidence but be part
of a broader strategy for evidence generation. As such,
complementary data obtained from other appropriately
designed alternatives conducted in Phase IV of the de-
velopment lifecycle are required to address limitations
in the external validity of RCTs post hoc. As recom-
mended by some of the studies included in this review
[15, 23, 36], the use of non-randomized observational
studies that utilize large healthcare databases can sup-
port RCT findings by determining treatment effective-
ness in routine clinical practice [6, 77]. Such studies
include a wide range of different designs including pro-
spective and retrospective cohort studies, case–control
studies, and cross-sectional studies in which any inter-
vention studied is determined by clinical practice and
not a rigid protocol [78]. Taken together, RCT and ob-
servational study data should provide a complementary
body of evidence that optimizes both internal and ex-
ternal validity.
The findings presented in this review must be viewed
within the limitations of the methodology employed.
Firstly, the search strategy did not define the outcomes
to be reported a priori and was influenced by the evi-
dence base identified. Secondly, there are no acknowl-
edged methods for the assessment of the quality of data
for this type of analysis. Thirdly, the present review was
limited to just three therapeutic areas (cardiology, men-
tal health, and oncology), and while a large proportion
of the relevant literature was focused in these areas, it
is possible that findings may be different in other spe-
cialties. In addition, to manage the scope of the review,
we restricted our eligibility criteria to studies that in-
cluded adults and assessed pharmaceutical interven-
tions only, and we cannot completely rule out the
possibility that findings might be different in pediatric
populations or other healthcare interventions. Finally,
the conclusions regarding external validity, as reported
in individual studies, were subjective, which limited our
ability to more accurately synthesize and summarize
the findings. The review strategy was, however, relevant
to the objective of the present analysis, as it utilized a
robust and transparent approach in order to identify
key concepts and the main sources of information
available on the representativeness of RCT patient sam-
ples and the external validity of RCT findings. The
framework for categorizing the methods used in indi-
vidual studies and for interpreting individual study con-
clusions was consistent and clearly detailed, adding to
the methodological rigor of the review.
Conclusions
In the majority of studies included in this literature re-
view it was concluded that patient samples in cardiology,
mental health, and oncology RCTs are not broadly rep-
resentative of patients encountered in everyday practice.
These findings suggest that, while explanatory RCTs still
represent the gold-standard primary study design for the
generation of clinical efficacy evidence, there is a need to
improve their external validity and/or supplement their
results with data from a range of research approaches
such that physicians treating patients in real-world set-
tings have the appropriate evidence on which to base
their clinical decisions and to provide greater insight re-
garding clinical effectiveness in everyday practice. This
goal could be achieved in two ways: (i) modification of
trial designs to include a patient sample more represen-
tative of the individuals expected to receive an interven-
tion in real life, while recognizing the potential
compromise of internal validity caused by increasing
heterogeneity as discussed above [68, 69]; and (ii) sup-
plementing RCT evidence with data generated from a
continuum of appropriately designed supportive studies
with alternative methodologies. In general, a thoughtful
approach to RCT design is required in which the trade-
offs between internal and external validity are considered
in a holistic and balanced manner so that the results can
better meet the diverse needs of regulators, prescribers,
payers, and patients.
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